The Change of Hallmark: An Update

Résumé fourni par la source

Still in 2011, Hanahan and Weinberg considered “Inducing angiogenesis” a hallmark of cancer [1]. Eleven years later, in 2022, Hanahan instead described a slightly revised hallmark: “Inducing or accessing vasculature” [1]. It may not appear to mark the end of an era, but the term “accessing” signals the end of the idea that any cancer can be treated by drugs aimed solely at preventing new vessel sprouting [2]. In a previous review [3], we showed how the exploitation—or “co-option”—of pre-existing normal vessels has evolved and impacted oncology, as the old paradigm of a single drug anti-angiogenic effective across all tumours no longer holds. Here, we present an update, focusing primarily—but not exclusively—on developments from the past three years.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.